Journal article
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Abstract
BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk.
METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined …
Authors
Ridker PM; Revkin J; Amarenco P; Brunell R; Curto M; Civeira F; Flather M; Glynn RJ; Gregoire J; Jukema JW
Journal
The New England Journal of Medicine, Vol. 376, No. 16, pp. 1527–1539
Publisher
Massachusetts Medical Society
Publication Date
April 20, 2017
DOI
10.1056/nejmoa1701488
ISSN
0028-4793